Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging angiogenesis: applications and potential for drug development.

Janet C Miller1, Homer H Pien, Dushyant Sahani

  • 1Department of Radiology, Massachusetts General Hospital, 100 Charles River Plaza, Boston, MA 02114, USA. jcmiller@partners.org

Journal of the National Cancer Institute
|February 3, 2005
PubMed
Summary

Imaging techniques offer a promising solution for accurately measuring anti-angiogenic drug effectiveness in cancer therapy. These biomarkers can help establish correct drug dosages and monitor treatment response efficiently.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pancreatic Cancer-Advances in the Last 50 Years.

World journal of surgery·2026
Same author

A multicenter multinational retrospective study of the 1-year natural history of LI-RADS 3 observations in patients with cirrhosis.

European radiology·2026
Same author

A Learning Accelerator Framework: Scalable Clinical Artificial Intelligence Development and Delivery.

Journal of the American College of Radiology : JACR·2025
Same author

Comparing multi-use syringeless and conventional single-use dual-syringe injectors in contrast-enhanced CT: efficiency, cost, and technologist satisfaction.

European radiology·2025
Same author

Early Experience With Postmortem CT Imaging.

Journal of computer assisted tomography·2025
Same author

Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline <i>ATM</i> Mutated Pancreatic Ductal Adenocarcinoma.

Advances in radiation oncology·2025

Area of Science:

  • Oncology
  • Medical Imaging
  • Pharmacology

Background:

  • Tumor growth and metastasis are critically dependent on angiogenesis (new blood vessel formation).
  • Targeting angiogenic vasculature with novel drugs is a key strategy in cancer therapy.
  • Clinical trials for anti-angiogenic agents face challenges in dosage determination and response assessment due to non-cytotoxic mechanisms and long evaluation times.

Purpose of the Study:

  • To review the potential of various imaging modalities as biomarkers for assessing anti-angiogenic therapy response.
  • To evaluate the utility of imaging in establishing drug dosage and monitoring clinical effects in cancer patients.

Main Methods:

  • Review of multiple imaging modalities: positron emission tomography (PET), x-ray computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and optical imaging.

Related Experiment Videos

  • Analysis of methods for deriving hemodynamic parameters (blood flow, blood volume) using pharmacokinetic modeling.
  • Examination of imaging data validity through correlations with established methods (e.g., microvessel density, pathology scores) and assessment of reproducibility.

    • Main Results:

    • Discusses advantages and disadvantages of different imaging techniques for visualizing angiogenic vasculature.
    • Evaluates analytic methods for quantifying hemodynamic changes in response to therapy.
    • Presents evidence on the reliability and correlation of imaging-derived parameters with clinical outcomes and pathological indicators.

    Conclusions:

    • Imaging holds significant potential for reliable and sensitive monitoring of anti-angiogenic cancer therapy.
    • Specific imaging methods are identified as most suitable for clinical trials and therapeutic response assessment.
    • The review highlights the application of imaging in ongoing and past clinical trials for anti-angiogenic drugs.